Accuray Incorporated (ARAY)
| Market Cap | 274.71M |
| Revenue (ttm) | 455.00M |
| Net Income (ttm) | -6.80M |
| Shares Out | 97.07M |
| EPS (ttm) | -0.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 372,920 |
| Open | 2.92 |
| Previous Close | 2.91 |
| Day's Range | 2.81 - 2.95 |
| 52-Week Range | 2.00 - 4.30 |
| Beta | 1.55 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+165.02%) |
| Earnings Date | Jan 31, 2024 |
About ARAY
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney,... [Read more]
Financial Performance
In 2023, Accuray's revenue was $447.61 million, an increase of 4.12% compared to the previous year's $429.91 million. Losses were -$9.28 million, 73.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ARAY stock is "Strong Buy" and the 12-month stock price forecast is $7.5.
News
Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System
MADISON, Wis. , Dec. 5, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation the...
Accuray Reports Fiscal 2024 First Quarter Financial Results
Company Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance MADISON, Wis. , Nov. 7, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ...
Accuray to Participate in the 14th Annual Jefferies London Healthcare Conference
MADISON, Wis. , Oct. 31, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 14th Annual Jefferies London Healthcare Conference.
Accuray to Report First Quarter Fiscal 2024 Financial Results on November 7, 2023
MADISON, Wis. , Oct. 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2024, ended September 30, 2023, during a conference...
Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China's National Medical Products Administration
MADISON, Wis. , Oct. 3, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system for t...
Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
MADISON, Wis. , Oct. 2, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has a 510(k) pending for an online adaptive therapy option*, Cenos™, for its Radixact ...
Accuray Opens New Global Training Center at Madison, WI Headquarters to Advance Radiotherapy Treatment Techniques Amid Growing Demand for Precision Cancer Care
Large classrooms and a hybrid, in-person/remote connection option will make it easier for more care providers to remain current on best practices and innovations in radiation therapy New center is par...
Accuray to Host Investor Day at ASTRO on October 3, 2023
MADISON, Wis. , Sept. 14, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a discussion with analysts and investors on Tuesday, October 3, 2023, in c...
Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market
The Radixact System, with the addition of the VitalHold functionality, provides clinicians with unmatched choice of radiation treatment delivery options in one device Treatment delivery versatility of...
Accuray Reports Fourth Quarter and Fiscal 2023 Financial Results
8% Q4 revenue growth; Record shipments for FY23; Company issues guidance for FY24 MADISON, Wis. , Aug. 9, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for...
Accuray to Report Fiscal Year-End 2023 Financial Results on August 9, 2023
SUNNYVALE, Calif. , July 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and fiscal year 2023, ended June 30, 2023, during a conferenc...
Accuray Incorporated Announces Its Addition to the Russell 2000® Index
SUNNYVALE, Calif. , June 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be includ...
Cognizant is Partnering with Accuray to Accelerate Corporate Transformation and Drive Operational Efficiency in Their Radiation Therapy Business
Partnership Will Support Accuray with SAP S/4HANA Implementation TEANECK, N.J. , June 21, 2023 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced that it is partnering with Accuray Incorporated ...
Accuray Announces Suzanne Winter Selected as One of the Top 50 Healthcare Technology CEOs of 2023
SUNNYVALE, Calif. , June 15, 2023 /PRNewswire/ -- The global Accuray Incorporated (NASDAQ: ARAY) team is proud to announce that president and CEO Suzanne Winter has been recognized by The Healthcare T...
Accuray CyberKnife® and TomoTherapy® Platforms Featured in More Than 55 Abstracts Presented at ESTRO 2023, Reinforcing Systems' Versatility, Efficiency and Effectiveness
Data Highlight Expanding Use of (Ultra) Hypofractionated Treatments, Benefits in Patient Care Made Possible by the Precision and Accuracy of Accuray Technologies SUNNYVALE, Calif. , May 17, 2023 /PRNe...
Accuray Reports Fiscal 2023 Third Quarter Financial Results
Company delivers record quarterly revenue and unit volume in Q3; Reiterates fiscal year guidance SUNNYVALE, Calif. , April 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported f...
Accuray to Report Third Quarter Fiscal 2023 Financial Results on April 26, 2023
SUNNYVALE, Calif. , April 13, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2023, ended March 31, 2023, during a conferenc...
Accuray Incorporated to Speak at 33rd Annual Oppenheimer Healthcare Conference
Company to Take Part in Fireside Chat Tuesday, March 14, 2023 at 1:00pm PST / 4:00pm EST SUNNYVALE, Calif. , March 8, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its parti...
Accuray to Participate in the Cowen 43rd Annual Health Care Conference
Company to Take Part in Fireside Chat Monday, March 6, 2023 at 10:30am PST / 1:30pm EST SUNNYVALE, Calif. , Feb. 21, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its partic...
Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SUNNYVALE, Calif. , Feb. 7, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conf...
Robert C. Kill Joins Accuray Board of Directors
SUNNYVALE, Calif. , Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Robert C.
Accuray Reports Fiscal 2023 Second Quarter Financial Results
Delivered strong Q2 performance amidst challenging macroenvironment; Reiterate fiscal year guidance SUNNYVALE, Calif. , Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today repor...
European Radiosurgery Center Munich Invests in Second Accuray CyberKnife® System to Support the Demand for High-Precision Radiosurgery Treatments
Center believes the CyberKnife System is the #1 tool for delivery of advanced radiosurgery treatments Selected the latest generation CyberKnife S7™ System to increase the number of indications they ca...
Accuray to Report Second Quarter Fiscal 2023 Financial Results on February 1, 2023
SUNNYVALE, Calif. , Jan. 18, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2023, ended December 31, 2022, after the marke...
Accuray Announces First Patient Treatments in New Zealand With the CyberKnife® System, the World's Only Robotic Radiation Therapy Delivery Device
Auckland Radiation Oncology Selected the Latest-Generation CyberKnife S7™ System to Deliver Precise Treatments More Quickly, so Patients Can Rapidly Return to the Activities They Enjoy SUNNYVALE, Cali...